Sepsis is the leading cause of hospital deaths worldwide, with approximately 11 million deaths per year, representing 20% of all global deaths (WHO). However, there is currently no tool that provides a binary result for the diagnosis of this disease and there is a clear need among medical professionals since current detection methods take between 6 hours and two days, rapidly decreasing the survival rate for every hour without treatment.
In order to address this global clinical need, Loop DX has developed a new in vitro cellular immunoassay that identifies sepsis after the first hour of bloodstream infection offering a solution 10 times faster and 3 times more effective.
Loop has validated their technology with more than 500 sepsis suspected patients in 5 International Hospitals in Barcelona, Madrid, París or Dnipro (Ukraine), and has already received the UKCA and Medical Products manufacturer license.
- Pilots: In 5 hospitals: Bellvitge, Parc Taulí, Princesa, Revini, Cochin
- Maturity: Industrialization
- Capital raised: 700.000€
- Company Valuation: 7,7 M€
- Open Round: Yes
Loop Dx is at the forefront of revolutionizing sepsis detection with their innovative lateral flow platform designed for early-phase diagnosis, called SeptiLoop. Unlike traditional methods that focus on pathogen identification, their approach measures the status and response of the immune system of the septic patient.
SeptiLoop can diagnose bacteremia as early as one hour after infection and throughout all stages of sepsis, enabling healthcare professionals an early detection and timely treatment initiation.
- Sector: Health tech
- Country: Spain
- Nº of workers: 8
